23Jul/13

UK's NICE calls for more data to consider Roche drug for a type of vasculitis – The Pharma Letter

UK’s NICE calls for more data to consider Roche drug for a type of vasculitis
The Pharma Letter
UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published draft guidance on Swiss drug major Roche’s (ROG: SOX) blockbuster cancer drug MabThera (rituximab), which is also licensed for inducing 
NICE demands more data from Roche for MabThera in rare autoimmune diseasePMLiVE

all 2 news articles »

23Jul/13

New organ donor memorial at Airedale Hospital – Ilkley Gazette


Ilkley Gazette

New organ donor memorial at Airedale Hospital
Ilkley Gazette
“We also hope to improve public awareness of the need for organ donation and encourage people to speak to their loved ones about their wishes and sign up to the organ donor register.” The memorial garden was unveiled by Rachel Wiseman, of NHS Blood 
Debate sparked by plans to boost organ transplantsNewbury Weekly News Group
‘Miracle’ Leedds mum waits for fourth transplantYorkshire Evening Post

all 3 news articles »

23Jul/13

'Everyone will be an organ donor' – The Irish Sun


The Irish Sun

‘Everyone will be an organ donor
The Irish Sun
A Department of Health spokesman said: “The Minister is encouraging individuals, groups or organisations to submit their views on the practical aspects of introducing this system of opt-out consent for organ donation by Friday September 20 on the 
Letter from Sen. Harsdorf: Saving lives through organ donationPierce County Herald
New ‘opt-out’ system over organ donorsHerald.ie
US Rep. Barletta was off-base with Obamacare criticisms: As I See ItPatriot-News
Morpeth Herald
all 5 news articles »
23Jul/13

PD-1 Antibodies – Healio

PD-1 AntibodiesHealioThis activity will review data on the efficacy, safety, and response patterns observed with PD-1 in patients with advanced melanoma. This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc.,…

22Jul/13

아스텔라스 면역억제제 '아스타그랍' 승인장기이식 거부반응 효과 …임상 3상 시험 … – 의약뉴스

아스텔라스 면역억제제 ‘아스타그랍’ 승인장기이식 거부반응 효과 …임상 3상 시험
의약뉴스
아스타그랍은 1일 1회 복용하는 경구약으로 바실릭시맙(basiliximab)을 포함하거나 혹은 포함하지 않고 마이코페노레이트 모페틸(mycophenolate mofetil)과 코르티코스테로이드(corticosteroids) 약물과 병용해 이식거부반응을 예방한다. 이번 승인은 1093명의 환자